OLIG2 inhibitors (Dana-Farber Cancer Institute/Massachusetts General Hospital)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameOLIG2 inhibitors (Dana-Farber Cancer Institute/Massachusetts General Hospital)
Drug Alias NameOLIG2 inhibitors (Dana-Farber Cancer Institute)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionOligodendrocyte transcription factor 2 inhibitors
TargetsOligodendrocyte transcription factor 2
Therapy Area/IndicationsGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteThe General Hospital Corporation D/B/A Massachusetts General Hospital
Active IndicationsN/A
Inactive IndicationsGlioma

Other Information

ATC CodeN/A
Related LinksN/A